However, the company said Syfovre commercial vials grew ~7% sequentially and projected a stable outlook for gross-to-net adjustments with “modest” quarterly increases as seen in a buy-and-bill ...

Generated $152.0 million in SYFOVRE U.S. net product revenue in the third quarter 2024. SYFOVRE commercial vials grew by approximately 7% quarter-over-quarter. SYFOVRE net selling price declined ...

Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Shares of Apellis Pharmaceuticals ( APLS 2.47%) are down by about 62% from the peak they reached in January. However, investment bank analysts who follow the drugmaker think its best days are still ...

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net sales from its eye ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...

During the third quarter, commercial vial demand for SYFOVRE grew by 7% quarter-over-quarter and SYFOVRE maintained its market leadership with 84,500 commercial vials shipped to physicians.

We remain confident in our long-term strategy and the significant opportunities ahead.” SYFOVRE commercial vials grew by approximately 7% quarter-over-quarter. SYFOVRE net ...